SRPT
Income statement / Annual
Last year (2024), Sarepta Therapeutics, Inc.'s total revenue was $1.90 B,
an increase of 52.97% from the previous year.
In 2024, Sarepta Therapeutics, Inc.'s net income was $235.24 M.
See Sarepta Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.90 B |
$1.24 B |
$933.01 M |
$701.89 M |
$540.10 M |
$380.83 M |
$301.03 M |
$154.58 M |
$5.42 M |
$1.25 M |
| Cost of Revenue |
$319.10 M
|
$150.34 M
|
$139.99 M
|
$97.05 M
|
$63.38 M
|
$56.59 M
|
$34.19 M
|
$7.35 M
|
$130,000.00
|
$146.19 M
|
| Gross Profit |
$1.58 B
|
$1.09 B
|
$793.02 M
|
$604.84 M
|
$476.72 M
|
$324.25 M
|
$266.84 M
|
$147.23 M
|
$5.29 M
|
-$144.94 M
|
| Gross Profit Ratio |
0.83
|
0.88
|
0.85
|
0.86
|
0.88
|
0.85
|
0.89
|
0.95
|
0.98
|
-115.68
|
| Research and Development Expenses |
$804.52 M
|
$877.39 M
|
$877.09 M
|
$771.18 M
|
$722.34 M
|
$560.91 M
|
$401.84 M
|
$166.71 M
|
$188.27 M
|
$146.39 M
|
| General & Administrative Expenses |
$557.87 M
|
$453.27 M
|
$451.42 M
|
$282.66 M
|
$317.88 M
|
$284.81 M
|
$209.98 M
|
$119.85 M
|
$81.20 M
|
$75.04 M
|
| Selling & Marketing Expenses |
$0.00
|
$28.60 M
|
$14.60 M
|
$7.70 M
|
$0.00
|
$0.00
|
-$2.22 M
|
$2.83 M
|
$2.55 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$557.87 M
|
$481.87 M
|
$451.42 M
|
$282.66 M
|
$317.88 M
|
$284.81 M
|
$207.76 M
|
$122.68 M
|
$83.75 M
|
$75.04 M
|
| Other Expenses |
$2.41 M
|
$1.56 M
|
$714,000.00
|
$706,000.00
|
$662,000.00
|
$849,000.00
|
-$656,000.00
|
$1.98 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$1.36 B
|
$1.36 B
|
$1.33 B
|
$1.05 B
|
$1.04 B
|
$846.57 M
|
$610.47 M
|
$290.44 M
|
$272.02 M
|
$221.44 M
|
| Cost And Expenses |
$1.68 B
|
$1.51 B
|
$1.47 B
|
$1.15 B
|
$1.10 B
|
$903.16 M
|
$644.66 M
|
$297.80 M
|
$272.15 M
|
$221.44 M
|
| Interest Income |
$71.77 M
|
$85.97 M
|
$16.49 M
|
$354,000.00
|
$2.97 M
|
$7.24 M
|
$6.81 M
|
$1.81 M
|
$507,000.00
|
$0.00
|
| Interest Expense |
$18.39 M
|
$22.01 M
|
$53.25 M
|
$63.53 M
|
$59.95 M
|
$30.67 M
|
$33.71 M
|
$5.78 M
|
$1.89 M
|
$0.00
|
| Depreciation & Amortization |
$37.72 M
|
$58.89 M
|
$54.60 M
|
$49.34 M
|
$39.74 M
|
$30.55 M
|
$12.25 M
|
$8.09 M
|
$5.61 M
|
$5.25 M
|
| EBITDA |
$316.89 M |
-$439.20 M |
-$582.12 M |
-$306.08 M |
-$453.38 M |
-$652.66 M |
-$316.66 M |
-$34.75 M |
-$261.12 M |
-$214.78 M |
| EBITDA Ratio |
0.17
|
-0.35
|
-0.51
|
-0.59
|
-0.98
|
-1.23
|
-1.14
|
-1.54
|
-49.2
|
-175.73
|
| Operating Income Ratio |
0.11
|
-0.22
|
-0.57
|
-0.64
|
-1.04
|
-1.37
|
-1.14
|
-1.11
|
-49.2
|
-175.73
|
| Total Other Income/Expenses Net |
$42.69 M
|
-$252.27 M
|
-$153.76 M
|
$40.76 M
|
$11.10 M
|
-$8.32 M
|
-$18.98 M
|
$123.01 M
|
-$535,000.00
|
$154,000.00
|
| Income Before Tax |
$260.77 M
|
-$520.10 M
|
-$689.96 M
|
-$418.95 M
|
-$553.07 M
|
-$713.88 M
|
-$362.61 M
|
-$48.63 M
|
-$267.27 M
|
-$220.03 M
|
| Income Before Tax Ratio |
0.14
|
-0.42
|
-0.74
|
-0.6
|
-1.02
|
-1.87
|
-1.2
|
-0.31
|
-49.3
|
-175.6
|
| Income Tax Expense |
$25.54 M
|
$15.88 M
|
$13.53 M
|
-$168,000.00
|
$1.06 M
|
$1.20 M
|
-$692,000.00
|
$2.06 M
|
-$7.62 M
|
-$5.25 M
|
| Net Income |
$235.24 M
|
-$535.98 M
|
-$703.49 M
|
-$418.78 M
|
-$554.13 M
|
-$715.08 M
|
-$361.92 M
|
-$50.69 M
|
-$267.27 M
|
-$220.03 M
|
| Net Income Ratio |
0.12
|
-0.43
|
-0.75
|
-0.6
|
-1.03
|
-1.88
|
-1.2
|
-0.33
|
-49.3
|
-175.6
|
| EPS |
2.47 |
-5.8 |
-8.03 |
-5.15 |
-7.11 |
-9.71 |
-5.46 |
-0.86 |
-5.49 |
-5.2 |
| EPS Diluted |
2.18 |
-5.8 |
-8.03 |
-5.15 |
-7.11 |
-9.71 |
-5.46 |
-0.86 |
-5.49 |
-5.2 |
| Weighted Average Shares Out |
$95.08 M
|
$92.40 M
|
$87.56 M
|
$81.26 M
|
$77.96 M
|
$73.62 M
|
$66.25 M
|
$58.82 M
|
$48.68 M
|
$42.29 M
|
| Weighted Average Shares Out Diluted |
$107.88 M
|
$92.40 M
|
$87.56 M
|
$81.26 M
|
$77.96 M
|
$73.62 M
|
$66.25 M
|
$58.82 M
|
$48.70 M
|
$42.29 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
